AstraZeneca Loses Bid To Overturn Prilosec Ruling
The appeals court on Tuesday affirmed the U.S. District Court for the Southern District of New York's May 2007 ruling that the company's omeprazole delayed-release capsules did not infringe two AstraZeneca patents for the branded version.
The patents-in-suit are U.S. Patent Numbers 4,786,505 and 4,853,230, which cover the Prilosec formulation.
“Once again, we...
To view the full article, register now.